TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Bergentoft Pharma Consulting AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
179
|
185 | |
| Financial expenses |
1
|
0 | |
| Earnings before taxes |
156
|
114 | |
| EBITDA |
155
|
114 | |
| Total assets |
359
|
264 | |
| Current assets |
273
|
174 | |
| Current liabilities |
56
|
69 | |
| Equity capital |
280
|
181 | |
| - share capital |
5
|
4 | |
| Employees (average) |
1
|
2
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
78.0%
|
68.6% | |
| Turnover per employee |
90
|
185 | |
| Profit as a percentage of turnover |
87.2%
|
61.6% | |
| Return on assets (ROA) |
43.7%
|
43.2% | |
| Current ratio |
487.5%
|
252.2% | |
| Return on equity (ROE) |
55.7%
|
63.0% | |
| Change turnover |
-6
|
79 | |
| Change turnover % |
-100%
|
-3%
|
75% |
| Chg. No. of employees |
-1
|
1
|
0 |
| Chg. No. of employees % |
-50%
|
100%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.